Is GUTS or RCKT more profitable?

Rocket Pharmaceuticals' return on equity of -52.77% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media refer more to GUTS or RCKT?

In the previous week, Fractyl Health had 12 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 16 mentions for Fractyl Health and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.60 beat Fractyl Health's score of 0.06 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 1 Very Positive mention(s) 0 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DMAC or GUTS more profitable?

DiaMedica Therapeutics' return on equity of -77.76% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% Fractyl Health N/A -1,362.10% -84.89%

Does the media prefer DMAC or GUTS?

In the previous week, Fractyl Health had 14 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 16 mentions for Fractyl Health and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.67 beat Fractyl Health's score of 0.06 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fractyl Health 1 Very Positive mention(s) 0 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, GUTS or OCGN?

Ocugen has higher revenue and earnings than Fractyl Health. Ocugen is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fractyl Health $90K 833.04 -$140.95M -$0.88 N/A Ocugen $4.58M 72.69 -$67.85M -$0.26 N/A

Is GUTS or OCGN more profitable?

Fractyl Health's return on equity of -1,362.10% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Ocugen N/A -127,987.80% -115.95%

Does the media refer more to GUTS or OCGN?

In the previous week, Fractyl Health had 15 more articles in the media than Ocugen. MarketBeat recorded 16 mentions for Fractyl Health and 1 mentions for Ocugen. Ocugen's average media sentiment score of 1.24 beat Fractyl Health's score of 0.06 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 1 Very Positive mention(s) 0 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RZLT or GUTS more profitable?

Rezolute's return on equity of -58.82% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Fractyl Health N/A -1,362.10% -84.89%

Does the media prefer RZLT or GUTS?

In the previous week, Fractyl Health had 15 more articles in the media than Rezolute. MarketBeat recorded 16 mentions for Fractyl Health and 1 mentions for Rezolute. Rezolute's average media sentiment score of 0.67 beat Fractyl Health's score of 0.06 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fractyl Health 1 Very Positive mention(s) 0 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GUTS or EBS?

In the previous week, Fractyl Health had 15 more articles in the media than Emergent Biosolutions. MarketBeat recorded 16 mentions for Fractyl Health and 1 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 0.39 beat Fractyl Health's score of 0.06 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 1 Very Positive mention(s) 0 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fractyl Health (GUTS) Competitors

$0.47 -0.01 (-2.39%)

As of 12:12 PM Eastern

Compare

GUTS vs. RCKT, DMAC, OCGN, RZLT, and EBS

Should you buy Fractyl Health stock or one of its competitors? Fractyl Health's main competitors and comparable companies include Rocket Pharmaceuticals (RCKT), DiaMedica Therapeutics (DMAC), Ocugen (OCGN), Rezolute (RZLT), and Emergent Biosolutions (EBS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fractyl Health compare to Rocket Pharmaceuticals?

Fractyl Health (NASDAQ:GUTS) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Fractyl Health currently has a consensus price target of $5.50, suggesting a potential upside of 1,067.73%. Rocket Pharmaceuticals has a consensus price target of $8.63, suggesting a potential upside of 218.85%. Given Fractyl Health's stronger consensus rating and higher possible upside, research analysts plainly believe Fractyl Health is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 8.4% of Fractyl Health shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fractyl Health has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	833.04	-$140.95M	-$0.88	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Rocket Pharmaceuticals' return on equity of -52.77% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

In the previous week, Fractyl Health had 12 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 16 mentions for Fractyl Health and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.60 beat Fractyl Health's score of 0.06 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fractyl Health has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Summary

Rocket Pharmaceuticals beats Fractyl Health on 8 of the 15 factors compared between the two stocks.

How does Fractyl Health compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Fractyl Health (NASDAQ:GUTS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Fractyl Health had 14 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 16 mentions for Fractyl Health and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.67 beat Fractyl Health's score of 0.06 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 8.4% of Fractyl Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

DiaMedica Therapeutics' return on equity of -77.76% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Fractyl Health	N/A	-1,362.10%	-84.89%

DiaMedica Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 60.19%. Fractyl Health has a consensus price target of $5.50, suggesting a potential upside of 1,067.73%. Given Fractyl Health's higher probable upside, analysts clearly believe Fractyl Health is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

DiaMedica Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

DiaMedica Therapeutics has higher earnings, but lower revenue than Fractyl Health. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Fractyl Health	$90K	833.04	-$140.95M	-$0.88	N/A

Summary

DiaMedica Therapeutics beats Fractyl Health on 8 of the 14 factors compared between the two stocks.

How does Fractyl Health compare to Ocugen?

Fractyl Health (NASDAQ:GUTS) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

10.3% of Ocugen shares are held by institutional investors. 8.4% of Fractyl Health shares are held by company insiders. Comparatively, 4.0% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Fractyl Health currently has a consensus price target of $5.50, indicating a potential upside of 1,067.73%. Ocugen has a consensus price target of $9.50, indicating a potential upside of 867.41%. Given Fractyl Health's higher possible upside, research analysts plainly believe Fractyl Health is more favorable than Ocugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Fractyl Health has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.2, indicating that its stock price is 120% more volatile than the broader market.

Fractyl Health's return on equity of -1,362.10% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Ocugen	N/A	-127,987.80%	-115.95%

Ocugen has higher revenue and earnings than Fractyl Health. Ocugen is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	833.04	-$140.95M	-$0.88	N/A
Ocugen	$4.58M	72.69	-$67.85M	-$0.26	N/A

In the previous week, Fractyl Health had 15 more articles in the media than Ocugen. MarketBeat recorded 16 mentions for Fractyl Health and 1 mentions for Ocugen. Ocugen's average media sentiment score of 1.24 beat Fractyl Health's score of 0.06 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fractyl Health beats Ocugen on 8 of the 15 factors compared between the two stocks.

How does Fractyl Health compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Fractyl Health (NASDAQ:GUTS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Rezolute's return on equity of -58.82% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Fractyl Health	N/A	-1,362.10%	-84.89%

83.0% of Rezolute shares are owned by institutional investors. 14.8% of Rezolute shares are owned by insiders. Comparatively, 8.4% of Fractyl Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Fractyl Health had 15 more articles in the media than Rezolute. MarketBeat recorded 16 mentions for Fractyl Health and 1 mentions for Rezolute. Rezolute's average media sentiment score of 0.67 beat Fractyl Health's score of 0.06 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rezolute has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market.

Rezolute has higher earnings, but lower revenue than Fractyl Health. Rezolute is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Fractyl Health	$90K	833.04	-$140.95M	-$0.88	N/A

Rezolute currently has a consensus target price of $9.38, suggesting a potential upside of 139.59%. Fractyl Health has a consensus target price of $5.50, suggesting a potential upside of 1,067.73%. Given Fractyl Health's higher probable upside, analysts clearly believe Fractyl Health is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Rezolute beats Fractyl Health on 9 of the 14 factors compared between the two stocks.

How does Fractyl Health compare to Emergent Biosolutions?

Fractyl Health (NASDAQ:GUTS) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Fractyl Health has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

78.4% of Emergent Biosolutions shares are held by institutional investors. 8.4% of Fractyl Health shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Emergent Biosolutions has higher revenue and earnings than Fractyl Health. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	833.04	-$140.95M	-$0.88	N/A
Emergent Biosolutions	$742.90M	0.45	$52.60M	-$3.55	N/A

Fractyl Health presently has a consensus target price of $5.50, indicating a potential upside of 1,067.73%. Emergent Biosolutions has a consensus target price of $10.00, indicating a potential upside of 51.86%. Given Fractyl Health's stronger consensus rating and higher possible upside, analysts clearly believe Fractyl Health is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Fractyl Health has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Emergent Biosolutions	-22.95%	16.35%	6.17%

In the previous week, Fractyl Health had 15 more articles in the media than Emergent Biosolutions. MarketBeat recorded 16 mentions for Fractyl Health and 1 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 0.39 beat Fractyl Health's score of 0.06 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fractyl Health beats Emergent Biosolutions on 8 of the 14 factors compared between the two stocks.

Get Fractyl Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GUTS vs. The Competition

Export

Metric	Fractyl Health	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$74.97M	$3.91B	$7.27B	$13.03B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.54	14.13	274.95	25.63
Price / Sales	833.04	1,446.16	669.16	97.27
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	6.73	15.01	10.32	6.26
Net Income	-$140.95M	-$22.82M	$3.49B	$360.12M
7 Day Performance	-20.28%	-2.72%	-1.33%	-0.42%
1 Month Performance	-37.20%	-7.12%	-3.71%	-3.75%
1 Year Performance	-52.30%	29.24%	14.41%	4.84%

Fractyl Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GUTS Fractyl Health	3.1676 of 5 stars	$0.47 -2.4%	$5.50 +1,060.3%	-51.1%	$75.61M	$90K	N/A	73	Gap Down
RCKT Rocket Pharmaceuticals	2.777 of 5 stars	$3.43 -2.1%	$8.63 +151.8%	-2.6%	$374.90M	N/A	N/A	202
DMAC DiaMedica Therapeutics	1.8952 of 5 stars	$6.88 +0.4%	$12.00 +74.5%	+10.2%	$372.01M	N/A	N/A	35
OCGN Ocugen	2.135 of 5 stars	$1.06 +2.4%	$9.50 +800.5%	-39.8%	$357.76M	$4.58M	N/A	116	Positive News
RZLT Rezolute	2.3322 of 5 stars	$3.70 -6.5%	$9.38 +153.7%	-53.1%	$355.80M	N/A	N/A	71	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GUTS) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fractyl Health (GUTS) Competitors

GUTS vs. RCKT, DMAC, OCGN, RZLT, and EBS

How does Fractyl Health compare to Rocket Pharmaceuticals?

Summary

How does Fractyl Health compare to DiaMedica Therapeutics?

Summary

How does Fractyl Health compare to Ocugen?

Summary

How does Fractyl Health compare to Rezolute?

Summary

How does Fractyl Health compare to Emergent Biosolutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fractyl Health (GUTS) Competitors

GUTS vs. RCKT, DMAC, OCGN, RZLT, and EBS

How does Fractyl Health compare to Rocket Pharmaceuticals?

Do analysts rate GUTS or RCKT?

Do insiders and institutionals hold more shares of GUTS or RCKT?

Which has higher earnings & valuation, GUTS or RCKT?

Is GUTS or RCKT more profitable?

Does the media refer more to GUTS or RCKT?

Which has more volatility & risk, GUTS or RCKT?

Summary

How does Fractyl Health compare to DiaMedica Therapeutics?

Does the media prefer DMAC or GUTS?

Do insiders & institutionals hold more shares of DMAC or GUTS?

Is DMAC or GUTS more profitable?

Do analysts prefer DMAC or GUTS?

Which has more risk & volatility, DMAC or GUTS?

Which has stronger earnings & valuation, DMAC or GUTS?

Summary

How does Fractyl Health compare to Ocugen?

Do institutionals & insiders have more ownership in GUTS or OCGN?

Do analysts rate GUTS or OCGN?

Which has more volatility and risk, GUTS or OCGN?

Is GUTS or OCGN more profitable?

Which has better earnings and valuation, GUTS or OCGN?

Does the media refer more to GUTS or OCGN?

Summary

How does Fractyl Health compare to Rezolute?

Is RZLT or GUTS more profitable?

Do insiders and institutionals hold more shares of RZLT or GUTS?

Does the media prefer RZLT or GUTS?

Which has more volatility and risk, RZLT or GUTS?

Which has stronger valuation & earnings, RZLT or GUTS?

Do analysts prefer RZLT or GUTS?

Summary

How does Fractyl Health compare to Emergent Biosolutions?

Which has more volatility and risk, GUTS or EBS?

Do insiders and institutionals believe in GUTS or EBS?

Which has preferable valuation & earnings, GUTS or EBS?

Do analysts prefer GUTS or EBS?

Is GUTS or EBS more profitable?

Does the media favor GUTS or EBS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools